A novel c-Met/EGFR bispecific targeting antibody drug conjugate for NSCLC

被引：1
|
作者：
Chen, Gang [1 ]
Li, Lingna [1 ]
Muyot, Pia [1 ]
Gros, Edwige [1 ]
Zhang, Yanliang [1 ]
Sun, Yingqing [1 ]
Zhang, Hong [1 ]
Fu, Yanwen [1 ]
Lee, Alice [1 ]
Cao, Jian [1 ]
Kaufmann, Gunnar [1 ]
Miao, Zhenwei [1 ]
机构：
[1] Concortis Biosyst, San Diego, CA USA
来源：
CANCER RESEARCH | 2015年 / 75卷
关键词：
D O I：
10.1158/1538-7445.AM2015-LB-002
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LB-002
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Novel targets mediating resistance to EGFR/c-Met tyrosine kinase inhibitors in NSCLC
    Jacobs, Ryan
    Fong, Jason
    Bomgarden, Ryan
    Rogers, John
    Puri, Neelu
    CANCER RESEARCH, 2012, 72
  • [22] Activation of c-Met by EGFR modulates invasive phenotypes in NSCLC
    Dulak, Austin M.
    Siegfried, Jill M.
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (06) : S226 - S226
  • [23] Balancing Selectivity and Efficacy of Bispecific Epidermal Growth Factor Receptor (EGFR) X c-MET Antibodies and Antibody-Drug Conjugates
    Sellmann, Carolin
    Doerner, Achim
    Knuehl, Christine
    Rasche, Nicolas
    Sood, Vanita
    Krah, Simon
    Rhiel, Laura
    Messemer, Annika
    Wesolowski, John
    Schuette, Mark
    Becker, Stefan
    Toleikis, Lars
    Kolmar, Harald
    Hock, Bjoern
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2016, 291 (48) : 25106 - 25119
  • [24] A novel bispecific c-MET/PD-1 antibody with therapeutic potential in solid cancer
    Sun, Zu-Jun
    Wu, Yi
    Hou, Wei-Hua
    Wang, Yu-Xiong
    Yuan, Qing-Yun
    Wang, Hui-Jie
    Yu, Min
    ONCOTARGET, 2017, 8 (17) : 29067 - 29079
  • [25] Novel targets mediating resistance to EGFR/c-Met tyrosine kinase inhibitors in NSCLC.
    Jacobs, Ryan
    Fong, Jason
    Moravec, David
    Botting, Greg
    Bomgarden, Ryan
    Rogers, John
    Viner, Rosa
    Blank, Michael
    Puri, Neelu
    CANCER RESEARCH, 2013, 73 (08)
  • [26] First in human dose-escalation trial with the c-MET targeting antibody-drug conjugate BYON3521
    Kotecki, N.
    van Herpen, C. M. L.
    Curigliano, C.
    Hendriks, M.
    Vermaas, T. C.
    Corrigan, L.
    Belli, C.
    Jungels, C.
    Desar, I. M. E.
    Koper, N. P.
    Schellens, J. H. M.
    Banerji, U.
    CANCER RESEARCH, 2023, 83 (08)
  • [27] Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET
    Neijssen, Joost
    Cardoso, Rosa M. F.
    Chevalier, Kristen M.
    Wiegman, Luus
    Valerius, Thomas
    Anderson, G. Mark
    Moores, Sheri L.
    Schuurman, Janine
    Parren, Paul W. H., I
    Strohl, William R.
    Chiu, Mark L.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2021, 296
  • [28] New Strategies and Applications for Drugs Targeting EGFR and c-Met
    Giovannetti, E.
    Leon, L. G.
    CURRENT DRUG TARGETS, 2014, 15 (14) : 1261 - 1262
  • [29] Combinatorial approaches targeting the EGFR family and c-Met in SCCHN
    Wang, Dongsheng
    Lu, Yue
    Nannapaneni, Sreenivas
    Griffith, Christopher C.
    Steuer, Conor
    Qian, Guoqing
    Wang, Xu
    Chen, Zhengjia
    Patel, Mihir
    El-Deiry, Mark
    Shin, Dong M.
    He, Xia
    Chen, Zhuo G.
    Saba, Nabil F.
    ORAL ONCOLOGY, 2021, 112
  • [30] Bispecific Centyrin simultaneously targeting EGFR and c-Met demonstrates improved activity compared to the mixture of single agents.
    Klein, Donna
    Jacobs, Steve
    Sheri, Moores
    Anderson, Mark
    Attar, Ricardo
    Barnakov, Alexander
    Brosnan, Kerry
    Bushey, Barbara
    Chevalier, Kristen
    Chin, Diana
    Cornejo, Carla
    Diem, Mike
    Hyun, Linus
    Kuhar, Elise
    McCabe, Francis
    Picha, Kristen
    Spinka-Doms, Tracy
    Swift, Edward
    O'Neil, Karyn
    CANCER RESEARCH, 2013, 73 (08)
12345